Shots:

• Takeda will receive $562M up front for divesting its non-core prescription pharmaceutical products targeting a variety of therapeutic categories sold predominantly in the EU and Canada
• The divested portfolio includes Takeda’s CV/ metabolic and anti-inflammatory therapeutic areas along with Calcium. The portfolio generated FY 2019 net sales of ~$260M
• The divestiture further enables Takeda’s EUCAN to focus on and drive strategic core growth areas. In Apr’2020- Takeda divested EUCAN’s non-core OTC products to Orifarm Group

­ Ref: Takeda | Image: Takeda